GET DAILY SIGNALSArriVent BioPharma (AVBP) Declines -45% After Phase 3 Trial Miss
Key Takeaways
- ArriVent BioPharma (AVBP) shares have declined roughly 45% over the last 30 days, from about $28.45 to near $15.70.
- The selloff was driven primarily by the October 6, 2026 failure of the Phase 3 FURVENT trial of lead drug candidate firmonertinib in first-line EGFR exon 20 insertion-mutated non-small cell lung cancer.
- Firmonertinib's 240 mg dose delivered a median progression-free survival of 11.0 months versus 9.5 months for chemotherapy, a difference that did not reach statistical significance.
- Analysts responded by cutting price targets and largely removing the exon 20 insertion opportunity from their valuation models, redirecting focus to the PACC program and the ADC pipeline.
- Over the quarter, the stock traded in a relatively narrow range before the trial readout, with the entire decline concentrated around the early-October announcement.
- For more detailed data, explore ArriVent's Price Targets, Earnings, and Forecast pages.
- Investors can also explore Trending AI Robots for AI-driven trading insights.
Company Background and Pipeline Focus
ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company based in Newtown Square, Pennsylvania, focused on developing and commercializing precision oncology medicines. Its lead candidate, firmonertinib, is an oral, brain-penetrant, mutation-selective EGFR tyrosine kinase inhibitor licensed from Shanghai Allist Pharmaceuticals, with which ArriVent holds ex-China rights. The drug is already approved in China for certain EGFR-mutant non-small cell lung cancer (NSCLC) indications and was being advanced globally for EGFR exon 20 insertion and PACC mutations.
Beyond firmonertinib, ArriVent is building an antibody-drug conjugate (ADC) pipeline, including ARR-217, a CDH17-targeted ADC partnered with Lepu Biopharma for gastrointestinal cancers, and ARR-002, a dual-target MUC16/NaPi2b ADC. Investors follow the stock primarily for the firmonertinib data catalysts and the company's emerging ADC optionality. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, AVBP has fallen approximately 45%, from a closing price of $28.45 on September 25, 2026 to around $15.70 in recent trading. The decline was abrupt: on October 6, 2026, shares dropped about 47% in a single session, from $28.46 to a close of $15.09, touching a 52-week low near $12.09 intraday on unusually heavy volume.
The quarterly trend tells a similar story. Through July, August, and September, the stock traded mostly in a $28 to $31 range as investors positioned ahead of the pivotal FURVENT readout. Because the stock was essentially range-bound before the early-October announcement, the quarterly decline of roughly 45–50% is almost entirely attributable to the same trial outcome that drove the 30-day move.
What Drove the Recent Selloff
The dominant catalyst was the failure of the global Phase 3 FURVENT trial. On October 6, 2026, ArriVent announced that firmonertinib monotherapy did not meet its primary endpoint of progression-free survival (PFS) by blinded independent central review in previously untreated patients with EGFR exon 20 insertion-mutated NSCLC. The 240 mg dose achieved median PFS of 11.0 months versus 9.5 months for platinum-based chemotherapy, with a hazard ratio of 0.75 that narrowly missed statistical significance.
Analysts attributed the miss in part to a stronger-than-expected chemotherapy control arm, which delivered roughly 9.5 months of PFS versus anticipated estimates of about 7.5 to 8 months. Secondary endpoints favored firmonertinib, including investigator-assessed PFS of 11.1 versus 7.1 months and a confirmed objective response rate of 60% versus 33%, with no new safety signals.
The news triggered a sharp re-rating. Multiple firms lowered their price targets, with Jefferies, Truist, and Guggenheim each moving their targets from around $45 to $18, and analysts removed the exon 20 insertion indication from their valuations. The stock subsequently staged a partial recovery before the late-October ESMO 2026 meeting, where ArriVent presented encouraging Phase 1 data for its ARR-217 ADC, showing a 44.8% objective response rate at the 6 mg/kg dose in heavily pretreated colorectal cancer patients.
Quarterly Context and Pipeline Reassessment
For most of the quarter, AVBP traded sideways in the $28 to $31 range, reflecting a balance between optimism over the firmonertinib readout and overhangs such as a $250 million at-the-market offering program announced in May 2026. The company also reported second-quarter 2026 results in August, widening its net loss as research and development spending rose.
The quarter's defining event was the FURVENT failure, which removed a key near-term value driver and forced a fundamental reassessment of the lead program. That reassessment redirected investor attention toward firmonertinib's second pivotal opportunity, the ALPACCA trial in EGFR PACC-mutant NSCLC, and toward the ADC pipeline, including ARR-217 and ARR-002, the latter of which began dosing its first patient in October.
What Investors Should Watch Next
Looking ahead, the key question is how ArriVent reprioritizes its pipeline after the FURVENT outcome. Investors will monitor the company's review of the complete FURVENT dataset and any update on the future development path for firmonertinib. The ALPACCA Phase 3 trial in EGFR PACC-mutant NSCLC remains the drug's principal remaining late-stage opportunity.
On the ADC side, further ARR-217 Phase 1b dose-optimization data is expected in 2027, and the early clinical progress of ARR-002 will be closely watched. Financial factors also matter: a clinical-stage company with no product revenue faces ongoing cash burn, and its financing strategy will be important given the at-the-market program and rising R&D costs. Upcoming quarterly earnings and any regulatory or partnership updates will further shape the outlook. From what I see, monitoring these catalysts closely remains essential.
Exploring Tickeron’s AI Tools for Biotech Analysis
In my analysis of names like AVBP, I often turn to Tickeron’s platform for additional perspectives. The AI Daily Buy/Sell Signals feature helps me review recent patterns and compare performance across similar clinical-stage companies. It provides a practical way to layer quantitative signals onto fundamental research without replacing it. This approach has become a regular part of how I evaluate volatile biotech opportunities.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
AVBP sees its 50-day moving average cross bearishly below its 200-day moving average
The 50-day moving average for AVBP moved below the 200-day moving average on October 19, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
AVBP moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AVBP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
AVBP broke above its upper Bollinger Band on October 23, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for AVBP entered a downward trend on September 25, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where AVBP's RSI Indicator exited the oversold zone, 11 of 12 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on AVBP as a result. In 29 of 35 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for AVBP just turned positive on October 21, 2026. Looking at past instances where AVBP's MACD turned positive, the stock continued to rise in 16 of 21 cases over the following month. The odds of a continued upward trend are 76%.
Following a +9.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where AVBP advanced for three days, in 124 of 156 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.823) is normal, around the industry mean (3.035). P/E Ratio (-5.915) is within average values for comparable stocks, (-1.360). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.535) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. AVBP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AVBP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement